
    
      To demonstrate that the infusion of bone marrow nucleated cells into the coronary sinus is
      safe as assessed by adverse event records.

      To assess the effect of the infusion of bone marrow nucleated cells on the clinical course of
      angina and heart failure as measured by QOL questionnaire, Minnesota Living with Heart
      Failure, NYHA and CCS classification and SPECT.

      To assess the effect of the infusion of bone marrow nucleated cells on heart function as
      measured by ejection fraction (EF) and left ventricular end-diastolic diameter (LVEDD) by
      ECHO.

      To assess the effect of the infusion of bone marrow nucleated cells on the area of ischemia
      as measured by myocardial SPECT studies and ECHO.
    
  